-
Something wrong with this record ?
Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides
SM Picksley, B Vojtesek, A Sparks, DP Lane
Language English Country Great Britain
Document type Research Support, Non-U.S. Gov't
Grant support
IZ1459
MZ0
CEP Register
PubMed
8058315
Knihovny.cz E-resources
- MeSH
- Immunochemistry MeSH
- Nuclear Proteins MeSH
- Cells, Cultured MeSH
- Molecular Sequence Data MeSH
- Mice MeSH
- Neoplasm Proteins metabolism MeSH
- Tumor Suppressor Protein p53 metabolism MeSH
- Peptide Fragments metabolism MeSH
- Proto-Oncogene Proteins c-mdm2 MeSH
- Proto-Oncogene Proteins MeSH
- Amino Acid Sequence MeSH
- Binding Sites MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
The function of p53 is modulated by binding to a number of cellular and viral proteins, such as MDM2 and SV40 large T antigen. An initial immunochemical characterization of the p53-MDM2 complex in a rat fibroblast cell line (Clone 6) suggested that the anti-p53 monoclonal antibody Bp53-19 failed to immunoprecipitate the complex, and only recognized a fraction of the available p53 protein. Following the recent identification of the Bp53-19 epitope at the N-terminal end of p53, in the vicinity of where MDM2 protein was known to bind, we investigated the possibility that Bp53-19 might identify a region of p53 that interacts with MDM2 protein. MDM2 was found to bind with great specificity to short synthetic peptides derived from the N-terminus of p53. Several p53 synthetic peptides libraries, and an alanine substitution series at the optimal binding site, were used to establish the MDM2 binding site, in fine detail, to the sequence TFSGLW (aa 18-23) in mouse and TFSDLW in man (aa 18-23). The key residues required for MDM2 binding are almost identical to those required for the monoclonal antibody Bp53-19 to bind and this region of p53 is recognised by many other anti-p53 antibodies.
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13026141
- 003
- CZ-PrNML
- 005
- 20130813092333.0
- 007
- ta
- 008
- 130806s1994 xxk d f 000 0eng||
- 009
- AR
- 035 __
- $a (PubMed)8058315
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Picksley, Steven M. $u Dept. of Biochemistry, Dundee University, UK
- 245 10
- $a Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides / $c SM Picksley, B Vojtesek, A Sparks, DP Lane
- 504 __
- $a Literatura
- 520 9_
- $a The function of p53 is modulated by binding to a number of cellular and viral proteins, such as MDM2 and SV40 large T antigen. An initial immunochemical characterization of the p53-MDM2 complex in a rat fibroblast cell line (Clone 6) suggested that the anti-p53 monoclonal antibody Bp53-19 failed to immunoprecipitate the complex, and only recognized a fraction of the available p53 protein. Following the recent identification of the Bp53-19 epitope at the N-terminal end of p53, in the vicinity of where MDM2 protein was known to bind, we investigated the possibility that Bp53-19 might identify a region of p53 that interacts with MDM2 protein. MDM2 was found to bind with great specificity to short synthetic peptides derived from the N-terminus of p53. Several p53 synthetic peptides libraries, and an alanine substitution series at the optimal binding site, were used to establish the MDM2 binding site, in fine detail, to the sequence TFSGLW (aa 18-23) in mouse and TFSDLW in man (aa 18-23). The key residues required for MDM2 binding are almost identical to those required for the monoclonal antibody Bp53-19 to bind and this region of p53 is recognised by many other anti-p53 antibodies.
- 590 __
- $a bohemika - dle Pubmed
- 650 02
- $a sekvence aminokyselin $7 D000595
- 650 02
- $a zvířata $7 D000818
- 650 02
- $a vazebná místa $7 D001665
- 650 02
- $a kultivované buňky $7 D002478
- 650 02
- $a imunochemie $7 D007120
- 650 02
- $a mužské pohlaví $7 D008297
- 650 02
- $a myši $7 D051379
- 650 02
- $a molekulární sekvence - údaje $7 D008969
- 650 02
- $a nádorové proteiny $x metabolismus $7 D009363
- 650 02
- $a jaderné proteiny $7 D009687
- 650 02
- $a peptidové fragmenty $x metabolismus $7 D010446
- 650 02
- $a protoonkogenní proteiny $7 D011518
- 650 02
- $a protoonkogenní proteiny c-mdm2 $7 D051736
- 650 02
- $a nádorový supresorový protein p53 $x metabolismus $7 D016159
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Vojtěšek, Bořivoj, $d 1960- $7 xx0001694 $u Masaryk Memoria Cancer Institute, Brno, Czech Republic
- 700 1_
- $a Sparks, Alison $u CRC Cell Transformation Group, Dept. of Biochemistry, Medical Sciences Institute, Dundee University, Dundee, UK
- 700 1_
- $a Lane, David P. $u CRC Cell Transformation Group, Dept. of Biochemistry, Medical Sciences Institute, Dundee University, Dundee, UK
- 773 0_
- $t Oncogene $x 0950-9232 $g Roč. 9, č. 9 (1994), s. 2523-2529 $p Oncogene $w MED00003600
- 773 0_
- $p Oncogene $g 9(9):2523-9, 1994 Sep $x 0950-9232
- 910 __
- $a ABA008 $b B 1746 $y 3 $z 0
- 990 __
- $a 20130806095201 $b ABA008
- 991 __
- $a 20130813092842 $b ABA008
- 999 __
- $a ok $b bmc $g 990029 $s 824549
- BAS __
- $a 3
- BMC __
- $x MED00003600 $i 0950-9232 $a 1994 $b 9 $c 9 $d 2523-2529 $m Oncogene $n Oncogene
- GRA __
- $a IZ1459 $p MZ0
- LZP __
- $a 2013-08/gvbo
